The FDA cited quality lapses in drug products, with Reuters publishing a report detailing issues concerning Medline.
Steady: 0 in the last 7 days
Updated oct 6
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA cited quality lapses in drug products, with Reuters publishing a report detailing issues concerning Medline.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA issued a warning to Medline over quality lapses in its drug products.1 source
FDA cited quality lapses in drug products, reported by Reuters regarding Medline.1 source
- The FDA issued a warning letter to Medline regarding CGMP violations at a facility.Sub-event
FDA cited quality lapses in drug products, with Reuters reporting on Medline issues.1 source
Keep exploring
The entities involved
Related events
- FDA rejected a drug application due to inadequate data, with Frances Kelsey involved in the review.
- Congress and the Senate are considering legislation affecting FDA submissions and drug patent rights.
- Litigation regarding FDA approval process.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.